# Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

> **NCT04480827** · PHASE1 · COMPLETED · sponsor: **Galmed Research and Development, Ltd.** · enrollment: 57 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Aramchol free acid tablet 600mg, single dose
- **DRUG:** Aramchol free acid tablet 300mg, bid

## Key facts

- **NCT ID:** NCT04480827
- **Lead sponsor:** Galmed Research and Development, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-13
- **Primary completion:** 2022-03-24
- **Final completion:** 2022-03-24
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480827, "Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04480827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*